Perrigo Confirms Patent Challenge for Generic Version of Jublia(R) Topical Solution 10%

DUBLIN, Oct. 1, 2018 -- (Healthcare Sales & Marketing Network) -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that, Valeant Pharmaceuticals North America LLC, Valeant Pharmaceuticals Ireland LTD., Dow Pharmaceuticals Sciences, Inc., and Kaken P... Biopharmaceuticals, Generics, FDA, Litigation Perrigo, Valeant Pharmaceuticals, efinaconazole, Jublia, onychomycosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news